Brad S. Kahl, MD
Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health
Member of the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Dr. Kahl is the Director of the University of Wisconsin Lymphoma Service and Leader of the Hematologic Maliganancy Disease Oriented Working Group. He received his medical degree from Tufts University where he was elected AOA. He completed all post-graduate training at the University of Wisconsin. Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.
Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He has numerous publications related to his lymphoma research and serves on the editorial board for Clinical Advances in Hematology and Oncology and the Journal of Clinical Oncology. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of ECOG study E4402, Rituximab Extended Schedule or Retreatment Trial (RESORT) and ECOG study E1405, VcR-CVAD plus rituximab maintenance for Mantle Cell Lymphoma.
Other Forward Lymphoma Team Members
Get More from Forward Lymphoma
Sign up to receive more information from Forward Lymphoma and the Carbone Cancer Center.
Download the Helping Lymphoma Patients with Research Focused on Psychological Recovery white paper.
Download the Determining Who is Right for Rituximab white paper.
Download the Using Stem Cells to Develop Patient Specific Treatments white paper.
